Taiwan’s Centers for Disease Control (CDC) announced, October 13, that there were 117 new post-vaccination adverse events reported, including three deaths, of which the youngest was a 24-year-old man with no history of chronic disease.
The CDC’s Central Epidemic Command Center (CECC) said that the 24-year-old Taichung City resident received the AstraZeneca shot on September 11, and developed symptoms of fever after returning home.
The man took antipyretics (fever medication) and the fever symptoms subsided on September 13. On September 29, family members found the man unresponsive in bed. The man was rushed to hospital having lost vital signs, and was declared dead after arrival.
The CECC said that an autopsy was performed on October 5, and the Institute of Forensic Medicine found that the deceased had signs of double ventricular enlargement and cardiomyopathy.
The Taichung City Health Bureau said that the case was the youngest of 123 post-vaccine deaths reported in the city to date. TCHB said it will take the initiative to issue condolences and assist the family to collect relevant medical records and apply for assistance from the Vaccine Injury Compensation Program (VICP). It will be up to the VICP to clarify whether the man’s death was related to the vaccine.
The other two fatalities reported by the CECC, October 13, consisted of a 77-year-old man who died 22 days after receiving the AstraZeneca vaccine, and a 75-year-old man with a history of heart disease who died on the same day he received the second dose of the Moderna vaccine.
*Just as deaths reported by the CDC as “COVID deaths” are not necessarily caused by, or related to the SARS-CoV-2 virus; deaths reported to the VAERS are not necessarily caused by, or related to the vaccines.
Taiwan English News is an independent publication with no corporate funding. If you found this article informative, and would like to support my work, please buy me a coffee or support me on Patreon. Subscribe to Taiwan English News for free to receive the latest news via email. Advertising queries are welcome. Share, like, comment below.